Biotech Values

[DewDiligence]

Speaking of taxes, ENTA’s guidance for its FY2017 tax rate is only 24%, thanks to the federal R&D tax credit (see link in #msg-128545809) and smallish royalty income on Viekira. So, in the short run, ENTA won’t benefit much from lower US corporate taxes.

Still, in 2018 and beyond, ENTA stands to benefit greatly from tax reform because, if there is no change in the tax code, ENTA's tax rate will presumably climb substantially as royalties on G/P start to flow in.